Sunvepra (generic name asunaprevir) is being considered for BC PharmaCare coverage. As part of this process, BC patients, caregivers, and patient groups have the opportunity to become a part of this drug review and share their opinions and perspectives with the decision makers.
The below treatment fact sheet was designed to give you more information about Sunvepra (asunaprevir). and to encourage you to submit your opinions about the hep C treatment and other treatments.
Sunvepra (asunaprevir) Facts
BC PharmaCare is considering Sunvepra as a treatment for the hep C genotype 1, 1b, or 4 infection.
Treatment Description: Sunvepra is a NS3/4A protease inhibitor that works by blocking a viral enzyme (protease) that enables the hep C virus to survive and replicate in host cells. It works in combination with other treatments, such as Daklinza (daclatasvir).
- Sunvepra +
- Daklinza +/-
- Pegylated interferon with ribavirin
Approximate Sustained Viral Response (SVR)/”Cure Rate”:
- 90.6% in treatment-naïve patients
- 82.4% in prior non-responders to pegylated interferon with ribavirin patients (hard to treat patients)
- 82.6% in pegylated interferon intolerant/ineligible patients (hard to treat patients)
- 93.2%-95.5% in patients with hep C genotype 1
- 100% in patients with hep C genotype 4 (Health Canada)
Sunvepra is taken orally twice daily
|1b||Sunvepra with Daklinza||Twice daily with Daklinza taken once daily|
|1 or 4||Sunvepra with Daklinza and peginterferon and ribavirin||Twice daily with Daklinza taken once daily, peginterferon taken once weekly, ribavirin twice daily|
Possible Length of Treatment: 24 weeks
HCV/HIV Co-infection: The safety and efficacy of Sunvepra have not been studied in HCV patients co-infected with HIV.
Common Side Effects of Sunvepra with Daklinza Reported in Clinical Trials:
- Tiredness (fatigue)
Drugs Sunvepra Should Not Be Taken With:
- Dependent on the cytochrome P450 enzyme 2D6 (CYP2D6) for clearance and for which elevated plasma concentrations are associated with serious health issues.
- Moderate or strong inducers and inhibitors of CYP3A.
- Strong inhibitors of organic anion transporting polypeptide (OATP) 1B1 or 2B1.
Please see Sunvepra’s product monograph for more information.
Sampling of Clinical Trials for Sunvepra with Daklinza:
|Clinical Trial||Patients||Treatment Regimen||SVR12*|
|HALLMARK QUAD||GT 1 prior non-responders (partial and null responders)||Sunvepra + Daklinza + Pegylated Interferon with Ribavirin||93.2%|
|GT 4 prior non-responders (partial and null responders)||100%|
|HALLMARK-DUAL||GT 1b treatment naive||Sunvepra + Daklinza||90%|
|GT 1b pegylated interferon with ribavirin (PR) non responder||82%|
|GT 1b PR ineligible/intolerant||82%|
|GT 1b with cirrhosis||84%|
|GT 1b without cirrhosis||85%|
|*In clinical trials for hepatitis C virus (HCV) infection treatments, the goal is to cure/achieve SVR (sustained viral response)/reduce the virus so that it can’t be detected in the blood and liver disease from hep C is stopped.|
Additional Resources about Sunvepra with Daklinza:
- Health Canada’s Summary Basis of Decision for Sunvepra
- BC PharmaCare’s Sunvepra drug information sheet
- Asunaprevir/Daclatasvir National Patient Consultation Webinar by CTAC on YouTube
The above resources were used to create this treatment fact sheet.